

FACTSHEET H1 2024



> 60
development
projects*



> 390
pharmaceutical
ingredients*



> 1,300
marketing
authorisations*




3,604
employees
worldwide*

* Figures: Status 30 Jun 2024

KEY FIGURES (IFRS)

		H1 2024	H1 2023	2023	2022	2021
Revenue	EUR million	578.5	582.1	1,135.4	1,024.8	942.9
Adjusted EBITDA	EUR million	153.0	168.0	310.2	359.8	351.1
Adjusted EBITDA-margin	%	26.4	28.9	27.3	35.1	37.2
Unadjusted EBITDA	EUR million	147.0	137.0	280.3	331.3	354.4
Unadjusted EBITDA-margin	%	25.4	23.5	24.7	32.3	37.6
Operating income	EUR million	102.9	94.7	182.9	243.7	298.5
Earnings before taxes	EUR million	90.7	66.9	106.0	216.3	293.0
Profit or (loss) for the period	EUR million	59.9	39.6	60.5	132.6	208.9
Earnings per share	EUR	1.13	0.75	1.16	2.49	3.89

DERMAPHARM SHARE IN COMPARISON



Source: Xetra closing prices


COMPANY PROFILE

Dermapharm is an innovative and fast-growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the company is based in Grünwald near Munich. In addition to the main site in Sandersdorf-Brehna near Leipzig, Dermapharm operates further production, development and sales sites within Europe, primarily in Germany. Dermapharm currently employs 3,604 people worldwide.

REASONS TO INVEST

- 01** Clear focus on **“Made in Europe”**
- 02** **High-growth pharmaceutical manufacturer** in selected, **profitable niche markets**
- 03** In-house **R&D competence**
- 04** Pipeline with **> 60 ongoing development projects**
- 05** **Successful track record** in acquisitions
- 06** Expansion of **international presence**

SHAREHOLDER STRUCTURE



FINANCIAL CALENDAR 2024

Publication of Q3 Quarterly Report	14 November 2024
Participation at the German Equity Forum conference	25 November 2024

FACTS ABOUT DERMAPHARM SHARE

Ticker symbol	DMP
Ticker Symbol Bloomberg	DMP:GR
Ticker Symbol Reuters	DMPG.DE
WKN	A2GS5D
ISIN	DE000A2GS5D8
Number of shares	53.84 Mio.
IPO	09 February 2018
Stock Exchange	Regulated Market (Prime Standard) of the Frankfurt Stock Exchange

CONTACT

Dermapharm Holding SE

Investor Relations & Corporate Communications
 Britta Hamberger
 Tel.: +49 (0)89 641 86 233, E-Mail: ir@dermapharm.com

NOTICE

This publication contains various statements concerning the future development of the Dermapharm Group. These statements are based on both assumptions and estimates. Our assumptions involve risks and uncertainties that could cause actual results to differ materially from those anticipated. There are no plans to update the forward-looking statements. Throughout this publication, apparent differences may occur due to mathematical rounding during addition.

THE THREE SEGMENTS OF DERMAPHARM HOLDING SE (INTEGRATED BUSINESS MODEL)



Branded pharmaceuticals

With more than 390 active pharmaceutical ingredients, Dermapharm markets more than 1,300 marketing authorisations. The range of medicinal products, medical devices and food supplements is specialised in selected therapeutic areas in which Dermapharm occupies a leading market position, particularly in Germany.


Other healthcare products

Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts and medicinal cannabis in its “Other healthcare products” segment. In this segment, Dermapharm can tap the expertise of Arkopharma, the market leader for herbal food supplements in France, and the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceutical industry, among others.

Parallel import business

Dermapharm’s business model also includes a “Parallel import business” segment, which is operated under the “axicorp” brand. Based on revenue, axicorp is currently the sixth largest parallel importer in Germany in the first half of 2024.


REVENUE BY SEGMENTS



2024 GUIDANCE:

Group Revenue **EUR 1,170 million to EUR 1,210 million** vs. previous year (EUR 1,135.4 million)

ADJUSTED EBITDA BY SEGMENTS



2024 GUIDANCE:

Adjusted Group EBITDA **EUR 305 million to EUR 315 million** vs. previous year (EUR 310.2 million)

ADJUSTED EBITDA MARGIN

